Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada.
+ 2 more risks
High growth potential with mediocre balance sheet.
Share Price & News
How has Yield10 Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: M6X2's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: M6X2 underperformed the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: M6X2 underperformed the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is Yield10 Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Yield10 Bioscience undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate M6X2's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate M6X2's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: M6X2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: M6X2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate M6X2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: M6X2 is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.5x).
How is Yield10 Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M6X2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: M6X2 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: M6X2's is expected to become profitable in the next 3 years.
Revenue vs Market: M6X2's revenue (67.4% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: M6X2's revenue (67.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if M6X2's Return on Equity is forecast to be high in 3 years time
How has Yield10 Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: M6X2 is currently unprofitable.
Growing Profit Margin: M6X2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: M6X2 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare M6X2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: M6X2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: M6X2 has a negative Return on Equity (-303.82%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Yield10 Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: M6X2's short term assets ($3.5M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: M6X2's short term assets ($3.5M) do not cover its long term liabilities ($5.0M).
Debt to Equity History and Analysis
Debt Level: M6X2 is debt free.
Reducing Debt: M6X2 has not had any debt for past 5 years.
Inventory Level: M6X2 has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if M6X2's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: M6X2 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: M6X2 has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.1% each year.
What is Yield10 Bioscience's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate M6X2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate M6X2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if M6X2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if M6X2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of M6X2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Olly Peoples (61yo)
Dr. Oliver P. Peoples, also known as Olly, Ph.D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi ...
CEO Compensation Analysis
Compensation vs Market: Olly's total compensation ($USD738.25K) is above average for companies of similar size in the German market ($USD413.42K).
Compensation vs Earnings: Olly's compensation has increased whilst the company is unprofitable.
|Co-Founder & Director||27.7yrs||US$60.96k||0.040% $2.2k|
|VP of Research & Chief Science Officer||3.3yrs||US$467.78k||0.14% $7.9k|
|VP of Planning & Corporate Communications and Secretary||3.3yrs||US$372.11k||0.15% $8.6k|
|VP of Finance||3.3yrs||US$251.94k||0.13% $7.2k|
Experienced Management: M6X2's management team is considered experienced (3.3 years average tenure).
|Co-Founder & Director||27.7yrs||US$60.96k||0.040% $2.2k|
|Independent Director||2.9yrs||US$65.96k||0.0097% $548.5|
|Independent Director||6.2yrs||US$43.46k||0.11% $6.4k|
|Independent Chairman of the Board||6.3yrs||US$85.96k||0.036% $2.0k|
|Chairman Emeritus||0yrs||US$83.81k||no data|
|Member of Scientific Advisory Board||3.4yrs||no data||no data|
|Member of Scientific Advisory Board||4yrs||no data||no data|
|Member of Scientific Advisory Board||1.6yrs||no data||no data|
|Director||0yrs||no data||no data|
Experienced Board: M6X2's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: M6X2 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35%.
Yield10 Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Yield10 Bioscience, Inc.
- Ticker: M6X2
- Exchange: DB
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.090m
- Listing Market Cap: US$5.643m
- Shares outstanding: 781.81k
- Website: https://www.yield10bio.com
Number of Employees
- Yield10 Bioscience, Inc.
- 19 Presidential Way
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|YTEN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2006|
|M6X2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2006|
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries. It also has an oilseed development center in Saskatchewan, Canada. Yield10 Bioscience, Inc. has a research agreement with J. R. Simplot Company to evaluate three novel yield traits in potato. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 21:19|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.